Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases-Reference-Cited by-同舟云学术

Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases

Published:2017-02-17 Issue:1 Volume:163 Page:159-166
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

van Nijnatten T. J. A.,Simons J. M.,Moossdorff M.,de Munck L.,Lobbes M. B. I.,van der Pol C. C.,Koppert L. B.,Luiten E. J. T.,Smidt M. L.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-017-4157-0.pdf

Reference15 articles.

1. Pilewskie ML, Morrow M (2014) Management of the clinically node-negative axilla: what have we learned from the clinical trials? Oncology (Williston Park) 28(5):371–378

2. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U, International Breast Cancer Study Group Trial i (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305. doi: 10.1016/S1470-2045(13)70035-4

3. Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg 264(3):413–420. doi: 10.1097/SLA.0000000000001863

4. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575. doi: 10.1001/jama.2011.90

5. van Nijnatten TJ, Schipper RJ, Lobbes MB, Nelemans PJ, Beets-Tan RG, Smidt ML (2015) The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur J Surg Oncol 41(10):1278–1287. doi: 10.1016/j.ejso.2015.07.020

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgery paradigm for locally advanced breast cancer following neoadjuvant systemic therapy;Frontiers in Surgery;2024-09-06

2. Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy;Breast Cancer Research;2024-07-31

3. Disección axilar dirigida tras tratamiento sistémico primario en cáncer de mama N1. Validación de la técnica y experiencia a los 4 años;Revista de Senología y Patología Mamaria;2024-07

4. Study of the dynamics of parameters of immune status in patients with breast cancer against the background of neoadjuvant chemotherapy;The Journal of V. N. Karazin Kharkiv National University, Series "Medicine";2024-06-28

5. Neoadjuvant Chemotherapy in Breast Cancer: Evaluation of the Impact on Surgical Outcomes and Prognosis;Cancers;2024-06-26